✦ LIBER ✦

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial

✍ Scribed by Madi, A; Fisher, D; Wilson, R H; Adams, R A; Meade, A M; Kenny, S L; Nichols, L L; Seymour, M T; Wasan, H; Kaplan, R; Maughan, T S

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

EC3 COST-MINIMIZATION ANALYSIS OF CAPECI

✍ G Perrocheau; M Ducreux; M Hebbar; M Ychou; G Lledo; T Conroy; R Faroux; JY Doui 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Irinotecan/5-FU/Leucovorin, Oxaliplatin/

✍ Maxine D. Fisher; Edward Chu 📂 Article 📅 2001 🏛 CIG Media Group, LP. 🌐 English ⚖ 84 KB

3012 ORAL Capecitabine + oxaliplatin (XE

✍ M. Rothenberg; M. Navarro; C. Butts; Y. Bang; J. Cox; R. Goel; S. Gollins; L. Si 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 79 KB

15LBA Intermittent versus continuous oxa

✍ R. Adams; R. Wilson; M.T. Seymour; A.M. Meade; A. Madi; J. Cassidy; D. Fisher; S 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

636 POSTER Initial safety findings from

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 258 KB

Addition of cetuximab to oxaliplatin-bas

✍ Timothy S Maughan; Richard A Adams; Christopher G Smith; Angela M Meade; Matthew 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 364 KB